Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
- 1 December 1998
- journal article
- Published by Elsevier in The Lancet
- Vol. 352 (9144) , 1877-1881
- https://doi.org/10.1016/s0140-6736(98)10190-3
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Prospects for Pandemic Influenza Control with Currently Available Vaccines and AntiviralsThe Journal of Infectious Diseases, 1997
- Design of Aromatic Inhibitors of Influenza Virus NeuraminidaseThe Journal of Infectious Diseases, 1997
- Amantadine and rimantadine resistance in influenza A virusesCurrent Opinion in Infectious Diseases, 1994
- 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitroAntimicrobial Agents and Chemotherapy, 1993
- Rational design of potent sialidase-based inhibitors of influenza virus replicationNature, 1993
- Selection and Characterization of a Neuraminidase-Minus Mutant of Influenza Virus and Its Rescue by Cloned Neuraminidase GenesVirology, 1993
- Resistance of Influenza A Virus to Amantadine and Rimantadine: Results of One Decade of SurveillanceThe Journal of Infectious Diseases, 1989
- Economic impact of influenza: The individual's perspectiveThe American Journal of Medicine, 1987
- Influenza: Quantifying morbidity and mortalityThe American Journal of Medicine, 1987
- Clinical manifestations and consequences of influenzaThe American Journal of Medicine, 1987